Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Zyla Life Sciences
| Metric | Zyla Life Sciences Healthcare |
|---|---|
| Quality Score | 31 / 100 |
| Revenue (latest) | $2M |
| Net income (latest) | $107M |
| Operating margin | −457.5% |
| Net margin | 6041.7% |
| Return on equity | −90.9% |
| Return on assets | 179.0% |
| Return on capital (ROCE) | −36.3% |
| Debt / equity | — |
| Revenue growth (YoY) | −94.2% |
| Altman Z″ (distress) | — |
| Accruals / assets | 177.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.